Hodgkin Lymphoma: How Treatment May CHANGE in 2023 | What You Should be Asking Your Doctor
Samantha Siegel, M.D. was diagnosed with Hodgkin lymphoma on her 38th birthday. After undergoing intense treatments, she reached a complete remission. But less than a year later, she relapsed. In this conversation, she leads a discussion with top Hodgkin lymphoma specialist, Dr. Matthew Matasar with Rutgers Cancer Institute, to look at emerging and most-promising therapy options for relapsed/refractory Hodgkin lymphoma patients and those newly-diagnosed.
The Leukemia & Lymphoma Society (LLS) and The Patient Story bring you this program out of the biggest blood cancer/disease conference every year where top doctors and researchers discuss the most important updates (American Society of Hematology, or ASH) which took place December 2022.
Thank you to The Leukemia & Lymphoma Society (LLS) for its support of our patient education program!
Full story & transcript → https://www.thepatientstory.co....m/medical-experts/la
Join Our Community:
Website : https://www.thepatientstory.com/
Facebook: @ThePatientStory
Instagram: @ThePatientStory
Twitter: @patient_story
Contents of this Video:
00:00 - Intro
03:32 - Tell us about your journey into medicine
04:53 - What’s new at ASH 2022 on Hodgkin’s lymphoma?
09:32 - How do chemotherapies and immunotherapies work?
14:21 - What does staging mean in cancer?
17:02 - Where do PET scans fit in the treatment plan?
20:52 - Where does radiation fit in all this?
23:28 - Survivorship & patient care
26:54 - Advances in treatment for relapsed/ refractory patients
30:09 - Any words of advice to patients and caregivers?
#cancerstories #cancerpatient #cancersurvivor #patientstories #thepatientstory #hodgkinslymphoma #hodgkinlymphoma #lymsm #cancerstaging #cancertreatment #cancertreatments #relapse #refractory
-
Category
No comments found